Current clinical practices for ovarian cancers

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 8, 2002, Pages 3-6

  Harper, Peter ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ALOPECIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; GYNECOLOGIC CANCER; HUMAN; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0036288143     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70166-8     Document Type: Conference Paper

References (19)

1. Promising new therapies in the treatment of advanced ovarian cancer
2. Cancer of the ovary
3. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials
4. Chemotherapy for advanced ovarian cancer: Overview of randomized trails
5. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
6. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
7. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: An interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
8. Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study
9. Randomized study of cyclophosphamide, doxorubicin, and cisplatin (CAP) vs single-agent carboplatin in ovarian cancer patients requiring chemotherapy: Interim results of ICON 2
10. ICON 2 and ICON 3 data in previously untreated ovarian cancer: Results to date
11. Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132
12. Recombinant human erythropoietin in the treatment of the anemia of cancer
13. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
14. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
15. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
16. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
17. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study
18. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian cancer: Long-term results of a phase II study